Raeven et al., 2018 - Google Patents
Molecular and cellular signatures underlying superior immunity against Bordetella pertussis upon pulmonary vaccinationRaeven et al., 2018
View HTML- Document ID
- 9906502342927244626
- Author
- Raeven R
- Brummelman J
- Pennings J
- Van Der Maas L
- Helm K
- Tilstra W
- Van Der Ark A
- Sloots A
- Van Der Ley P
- Van Eden W
- Jiskoot W
- Van Riet E
- Van Els C
- Kersten G
- Han W
- Metz B
- Publication year
- Publication venue
- Mucosal immunology
External Links
Snippet
Mucosal immunity is often required for protection against respiratory pathogens but the underlying cellular and molecular mechanisms of induction remain poorly understood. Here, systems vaccinology was used to identify immune signatures after pulmonary or …
- 230000002685 pulmonary 0 title abstract description 147
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Raeven et al. | Molecular and cellular signatures underlying superior immunity against Bordetella pertussis upon pulmonary vaccination | |
| Manjaly Thomas et al. | Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial | |
| Zhu et al. | Tuberculosis vaccines: Opportunities and challenges | |
| Smits et al. | Different T cell memory in preadolescents after whole-cell or acellular pertussis vaccination | |
| Xin et al. | Subunit vaccine consisting of multi-stage antigens has high protective efficacy against Mycobacterium tuberculosis infection in mice | |
| Liu et al. | IL-2 restores T-cell dysfunction induced by persistent Mycobacterium tuberculosis antigen stimulation | |
| Zhuang et al. | Next-generation TB vaccines: progress, challenges, and prospects | |
| Guo et al. | CD4+ and CD8+ T cell-and IL-17-mediated protection against Entamoeba histolytica induced by a recombinant vaccine | |
| CN104736555B (en) | Mtb vaccine | |
| Dey et al. | A booster vaccine expressing a latency-associated antigen augments BCG induced immunity and confers enhanced protection against tuberculosis | |
| Raeven et al. | Molecular signatures of the evolving immune response in mice following a Bordetella pertussis infection | |
| Lin et al. | Characterization of conserved combined T and B cell epitopes in Leptospira interrogans major outer membrane proteins OmpL1 and LipL41 | |
| O’Gorman et al. | The Split Virus Influenza Vaccine rapidly activates immune cells through Fcγ receptors | |
| Feng et al. | Enhanced protection against Q fever in BALB/c mice elicited by immunization of chloroform-methanol residue of Coxiella burnetii via intratracheal inoculation | |
| Palaniappan et al. | Differential PsaA-, PspA-, PspC-, and PdB-specific immune responses in a mouse model of pneumococcal carriage | |
| Su et al. | Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models | |
| Carbonetti et al. | Highlights of the 11th International Bordetella symposium: from basic biology to vaccine development | |
| Bakhshaei et al. | Investigation of the cellular immune response to recombinant fragments of filamentous hemagglutinin and pertactin of Bordetella pertussis in BALB/c mice | |
| CN109069535A (en) | Saltant type Bordetella bacterial strain and its application method | |
| JP2019513722A5 (en) | ||
| Grasse et al. | GM-CSF improves the immune response to the diphtheria-component in a multivalent vaccine | |
| Gregory et al. | Epitope-based vaccination against pneumonic tularemia | |
| CN116003540B (en) | Preparation and application of mycobacterium tuberculosis antigen composition PFHP010 | |
| Tomoda et al. | Immune responses to Bordetella pertussis infection and vaccination | |
| Hemmi et al. | Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology |